Lechleiter takes up Big Pharma's torch to 'debunk' negative myths

Lilly CEO John Lechleiter

Eli Lilly & Co. ($LLY) CEO John Lechleiter has often come to the defense of the pharma business. He even did a lobbying tour in Europe when Germany instituted tough new cost-effectiveness measures back in 2011. Now, he's trying to debunk the "Five Big Myths" about Big Pharma. In a Forbes column, Lechleiter takes on the claim that R&D spending is exaggerated to justify high prices--plus four more. Report